Top Markets
#1 Siren Siren +38.43%
#2 RedStone RedStone +23.87%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +22.65%
#4 Ocean Protocol Ocean Protocol +15.39%
#5 Cysic Cysic +14.92%
#6 Arowana Arowana +13.88%
#7 Verus Coin Verus Coin +13.51%
#8 Perle Perle +11.75%
#9 KUB Coin KUB Coin +11.63%
#10 Wiki Cat Wiki Cat +10.25%
Coin of the day
Siren Siren
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Intensity Therapeutics, Inc. Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc.

INTS
Kedudukan dalam Saham #32095
Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical... Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical development phase, dedicated to discovering, advancing, and commercializing pharmaceutical treatments for solid tumor cancers. The company's primary experimental compound, INT230-6, is presently undergoing Phase 2 clinical trials. This investigational drug targets a range of difficult-to-treat solid tumors, including those affecting the pancreas, colon, bile duct, as well as squamous cell, sarcoma, breast, and liver cancers. Intensity Therapeutics has formed strategic collaborations with major pharmaceutical companies and research institutions: A partnership with Merck Sharpe & Dohme Corp. focuses on evaluating INT230-6 in conjunction with Keytruda for advanced pancreatic, colon, squamous cell, and bile duct malignancies. Another collaboration with Bristol-Myers Squibb Company is dedicated to studying INT230-6 combined with Yervoy in patients suffering from advanced liver, breast, and sarcoma cancers. Furthermore, the company is working with the Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research on a randomized controlled Phase II neoadjuvant study of INT230-6 for women diagnosed with early-stage breast cancer. Established in 2012, Intensity Therapeutics maintains its corporate headquarters in Westport, Connecticut.
Harga Saham
$4.12
Disegerakkan terakhir: 2026-08-17
Modal Pasaran
$11.14M
Perubahan (1 hari)
4.04%
Perubahan (1 tahun)
-45.79%
Negara
US
Perdagangan Intensity Therapeutics, Inc. (INTS)

Kategori

Healthcare
Pendapatan untuk Intensity Therapeutics, Inc. (INTS)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Intensity Therapeutics, Inc., pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Intensity Therapeutics, Inc. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR